What is the primary purpose of this 10-Q filing for Bristol Myers Squibb?

This 10-Q filing provides a quarterly update on Bristol Myers Squibb's financial performance, financial condition, and significant business developments for the period ending September 29, 2021. It is a crucial document for investors to assess the company's recent operational results and potential future outlook.

Where can I find detailed information on Bristol Myers Squibb's revenue and profitability for the quarter?

The 'Consolidated Statements of Earnings and Comprehensive Income/(Loss)' within Part I of the filing will detail the company's revenues, cost of sales, operating expenses, and net earnings. The 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' section will provide a narrative explanation of these financial results.

What are the key risks or legal matters Bristol Myers Squibb is currently facing?

Investors can find information on potential risks and legal proceedings in Part II of the filing. Item 1A, 'Risk Factors,' outlines significant risks that could materially affect the company's business, financial condition, or results of operations. Item 1, 'Legal Proceedings,' will detail any significant ongoing legal matters.

How can I understand Bristol Myers Squibb's cash flow generation and financial health?

The 'Consolidated Statements of Cash Flows' in Part I will show how the company generated and used cash during the quarter, broken down into operating, investing, and financing activities. The 'Consolidated Balance Sheets' will provide a snapshot of the company's assets, liabilities, and equity at the end of the reporting period, offering insights into its overall financial health.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q3 FY2021

Summary

Bristol Myers Squibb (BMY) reported its financial results for the quarter ending September 29, 2021. The company demonstrated solid operational performance, with key drivers likely stemming from its diverse product portfolio and strategic advancements. Investors should pay close attention to the company's revenue growth, particularly from its key therapeutic areas, and its ability to manage operating expenses effectively. The report also provides insights into the company's financial condition, cash flow generation, and significant legal or risk factors that could impact future performance. Overall, the filing suggests a company navigating a dynamic market, with a focus on product innovation and commercial execution. Investors are encouraged to review the Management's Discussion and Analysis section for a deeper understanding of the operational drivers, the company's strategic outlook, and any potential headwinds or tailwinds that management anticipates. The balance sheet and cash flow statements will offer further clarity on the company's financial health and its capacity for future investments or shareholder returns.

Financial Highlights

57 data points

Beta

Revenue

$11.62B

0.8% Gross Margin

Net Income

$1.55B

0.1% Net Margin

EPS (Diluted)

$0.69

Total Assets

$110.89B

Cash & Equivalents

$13.54B

Free Cash Flow

$5.00B

Financial Statements

Beta

Revenue	$11.62B
Cost of Revenue	$2.29B
Gross Profit	$9.33B
R&D Expenses	$2.98B
SG&A Expenses	$1.79B
Operating Expenses	$9.47B
Interest Expense	$328.00M
Net Income	$1.55B
EPS (Basic)	$0.70
EPS (Diluted)	$0.69
Shares Outstanding (Basic)	2.22B
Shares Outstanding (Diluted)	2.24B

Key Highlights

1The filing covers the quarterly report for the period ending September 29, 2021.
2Key financial statements, including Consolidated Statements of Earnings, Balance Sheets, and Cash Flows, are presented.
3Management's Discussion and Analysis of Financial Condition and Results of Operations is a core component, offering insights into performance drivers.
4The report details Quantitative and Qualitative Disclosures About Market Risk, highlighting BMY's exposure to various market factors.
5Information on Legal Proceedings and Risk Factors provides transparency into potential challenges and uncertainties.
6The filing includes details on Controls and Procedures, emphasizing the company's commitment to internal controls.
7Exhibits and a Summary of Abbreviated Terms are provided for further reference and clarity.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2021

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions